XML 47 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Income Taxes (Tables)
12 Months Ended
Jul. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation
           
    Fiscal Year Ended July 31,  
    2025     2024  
US federal statutory rates     21.0%       21.0%  
Permanent differences     (0.8% )     (7.1% )
Changes in deferred tax asset – stock-based compensation and options     (4.6% )     9.8%  
Valuation allowance     (15.6% )     (23.7% )
Effective tax rate     0.0%       0.0%  
Schedule of components of income tax expense (benefit)
           
    Fiscal Year Ended July 31,  
    2025     2024  
Current income taxes (benefit)   $ (668,300 )   $ 268,300  
Deferred income taxes (benefit)     397,200       (482,800 )
Increase in valuation allowance     (271,100     (214,500 )
Total   $     $  
Schedule of net deferred tax assets
           
    Fiscal Year Ended July 31,  
    2025     2024  
Cost of in-process research and development     4,049,100       4,049,100  
Stock-based compensation and options     1,442,600       1,501,300  
Impairment of investment – Oragenics, Inc. preferred stock     2,720,600       2,720,600  
Unrealized losses on investment – Oragenics, Inc. common stock           344,100  
Allowance for doubtful accounts     11,400       5,800  
Net operating loss carryforwards     4,230,000       3,561,700  
Total deferred tax assets     12,453,700       12,182,600  
Valuation allowance     (12,453,700     (12,182,600 )
Net deferred tax asset   $     $